▶ HUMANIN · SUBTOPIC · DOSING LITERATURE

HUMANIN Dosing Literature

For Laboratory Research Use Only. The content below describes dose ranges as reported in peer-reviewed publications. This page does not recommend any dose for human use. No clinical claim is made. Always consult the original source publication.

SCOPE OF THIS PAGE

This page documents the published-literature dose ranges that appear in trials and animal studies of HUMANIN. Every dose mention is bound to a citation (author, year, PMID where available). The PEPPUDEX wiki phrases these as descriptive observations of the research record, not as instructions to the reader.

ROUTES OF ADMINISTRATION IN PUBLISHED RESEARCH

The published research record for HUMANIN reports the following route(s) of administration: Subcutaneous (research), Intracerebroventricular (preclinical). Route selection in a study reflects pharmacokinetic considerations specific to that protocol and is not a recommendation for any human use of HUMANIN.

PHARMACOKINETIC HALF-LIFE

Published pharmacokinetic data report a half-life for HUMANIN of approximately Short (minutes) plasma · longer in CNS. Half-life is the kinetic parameter that frames the dosing rhythm chosen in trial design. It is a measurement, not a recommendation.

CITED DOSE RANGES IN THE LITERATURE

The peer-reviewed sources below report dose ranges, frequencies, and durations used in studies of HUMANIN. Refer to the original publication for full protocol detail.

Hashimoto Y, Niikura T, Tajima H, et al. (2001) reports the HUMANIN protocol used in A rescue factor abolishing neuronal cell death by a wide spectrum of familial Alzheimer's disease genes and Abeta, published in Proc Natl Acad Sci U S A. PMID 11371646. See the source for the protocol-level dose range, frequency, and duration. link
Muzumdar RH, Huffman DM, Atzmon G, et al. (2009) reports the HUMANIN protocol used in Humanin: a novel central regulator of peripheral insulin action, published in PLoS One. PMID 19470690. See the source for the protocol-level dose range, frequency, and duration. link
Lee C, Wan J, Miyazaki B, Fang Y, Guevara-Aguirre J, Yen K, Longo VD, Bartke A, Cohen P (2014) reports the HUMANIN protocol used in IGF-I regulates the age-dependent signaling peptide humanin, published in Aging Cell. See the source for the protocol-level dose range, frequency, and duration. link

DOSING Q+A FROM LITERATURE

The questions below summarise dosing-relevant entries from the literature record. Each answer is descriptive of published material and is not a recommendation.

▶ What's the dose in research?

Preclinical animal-model research has used SC humanin at 5-10 nmol/kg/day. Human dosing is not established. This wiki does not recommend any human dose.

STORAGE OF THE REFERENCE COMPOUND

Lyophilized · -20 °C 24 months

Reconstituted · 2-8 °C, 14-28 days

Storage conditions describe the stability of the research-grade reference material, not a dosing protocol.

RECONSTITUTION MATH (CALCULATOR)

The PEPPUDEX reconstitution calculator at /calculator returns volume-per-dose math given vial mg, BAC mL, and a target dose in mcg. The calculator performs arithmetic only. It does not recommend a dose. Any number entered by a researcher must come from their own protocol design or the cited literature.

REGULATORY CONTEXT

FDA · Not FDA-approved. Research-use only.

WADA · Not currently listed on the WADA Prohibited List.

◀ HUMANIN OVERVIEW MECHANISM ▶SAFETY PROFILE ▶

▶ LAST UPDATED · 2026-05-19